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Abstract
Introduction: GeneXpert (GX) is a novel, integrated, cartridge-based, nucleic acid amplification test with an established role for 
rapid diagnosis of Mycobacterium tuberculosis and detection of rifampicin resistance.
Aim: To evaluate the role of GX in pulmonary and extrapulmonary tuberculosis (TB) cases.
Material and methods: A prospective study was conducted in the pulmonary medicine department of a tertiary care hospital 
after the Ethics Comittee permission. Data of 257 presumptive TB patients was retrieved for GX, acid fast bacilli smear and cul-
ture (AFB smear and culture) and drug susceptibility test (DST). Sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) of GX in diagnosis and determination of rifampicin resistance in pulmonary and extrapulmonary TB cases 
were calculated and compared with culture and DST results.
Results: Our study included 132 pulmonary and 125 extrapulmonary cases. On the basis of clinicoradiological and microbiological 
correlation, diagnosis of TB was confirmed in 104 pulmonary and 103 extrapulmonary cases. Out of a total of 104 pulmonary 
TB cases, 73 were rifampicin-sensitive and 31 were rifampicin-resistant cases. 103 extrapulmonary TB patients included 66 
rifampicin-sensitive and 37 rifampicin-resistant cases. The sensitivity, specificity, PPV, NPV of GX in diagnosis and detection 
of rifampicin resistance in pulmonary TB was 95%, 93%, 98%, 84% and 96%, 100%, 100%, 96%, respectively. The sensitivity, 
specificity, PPV, NPV of GX in diagnosis and detection of rifampicin resistance in extrapulmonary TB cases was 79%, 86%, 96%, 
47% and 97%, 95%, 97%, 95%, respectively.
Conclusions: GX results are superior to smear microscopy and comparable to culture with shorter turnaround time.We recom-
mend using it in routine TB diagnosis as this will expedite the management of patients with presumptive TB.
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Introduction
Tuberculosis remains a major health problem 
accounting for millions of new cases and deaths 
every year worldwide. Therefore, rapid detec-
tion of Mycobacterium tuberculosis (MTB) and 
rifampicin resistance in presumptive TB cases is 
essential for the early diagnosis and treatment, 
thereby reducing the risk of transmission of 
the disease, mortality rates and emergence of 
drug-resistant TB. AFB culture is considered as 
the gold standard test for final determination of 
TB but the turnaround time is 2–8 weeks, and 
it requires trained personnel and expensive lab 
equipment [1]. Smear microscopy for acid fast 
bacilli (AFB) is one of the rapid and inexpensive 
tests available, but it has poor sensitivity and 
poor predictive value in the diagnosis of both 
pulmonary and extrapulmonary tuberculosis [2, 
3]. Thus, rapid identification, which is essential 
for early treatment, improves patient outcomes, 
and more effective public health intervention 
relies on nucleic acid amplification techniques.
The GeneXpert MTB/RIF (rifampicin) assay is 
a novel, integrated, cartridge-based, nucleic acid 
amplification test (CBNAAT) for rapid diagnosis 
of MTB and quick detection of rifampicin resis-
tance in both pulmonary and extrapulmonary 
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samples [4–6]. GeneXpert (GX) test has been 
developed and launched by a foundation for 
innovative new diagnostics (FIND) and Cepheid 
Corporation in 2004. However, the development 
of the GeneXpert test was completed in 2008. The 
World Health Organisation (WHO) endorsed the 
GeneXpert for the use in TB endemic countries 
in December 2010 declaring it a major milestone 
for global diagnosis of tuberculosis [7].
The test isolates Mycobacterium genome from 
captured bacteria and amplifies DNA (deoxynu-
cleic acid) using polymerised chain reaction. 
GeneXpert test identifies relevant 81bp (base 
pair) fragment of MTB rpoB gene using floures-
cent probes called molecular beacons. GeneXpert 
assay detects MTB by polymerise chain reaction 
(PCR) amplification of rpo gene and determination 
of rifampicin resistance by subsequent probing of 
this region for mutations that are associated with 
rifampicin resistance [8, 9]. Turnaround time of 
the test is 90 mins. GeneXpert requires approxi-
mately 130 bacilli per ml of sputum for positive 
result, whereas Ultra test needs 16 bacilli per ml 
of sputum for the test to be positive. It is specific 
for MTB complex; i.e., it can differentiate MTB 
from other mycobacteria. For each specimen, the 
test is carried out in a closed system (cartridge), 
so there is a reduced risk of cross-contamination 
and human error.
Several studies have showed successful use 
of GeneXpert test on pulmonary and extrapulmo-
nary samples with high sensitivity and specificity 
[10, 11]. However, fewer false positive and false 
negative results of GeneXpert have also been re-
ported recently, hence we decided to study and 
analyse its diagnostic accuracy in pulmonary and 
extrapulmonary TB.
Material and methods
We conducted a prospective study over a pe-
riod of 2 years (1/9/2015–1/9/2017) in the pul-
monary medicine department of a tertiary care 
hospital after the Ethics Comittee permission. 
Data of 257 consecutive presumptive TB patients 
(pulmonary and extrapulmonary) was retrieved 
for GeneXpert, AFB culture and drug susceptibil-
ity test (DST). Demographic data, clinical history, 
examination findings and radiological tests of 
these patients were also noted. Extrapulmonary 
cases included in our study were lymph node TB 
cases, TB pleural effusion cases, TB spine cases, 
other bone TB cases and TB meningitis cases. Pre-
sumptive TB pleural effusion cases were subject-
ed to closed needle pleural biopsy and pleural 
biopsy samples were analysed for GeneXpert and 
AFB smear and culture tests. All cases involved in 
the study had clinical and radiological signs con-
sistent with TB. Diagnosis of TB was made with 
the help of clinicoradiological correlation and 
microbiological tests positivity. Patients having no 
or incomplete data were excluded from the study. 
Sensitivity, specificity, negative predictive value 
and positive predictive value of GeneXpert in 
diagnosis and determination of rifampicin resis-
tance in pulmonary and extrapulmonary TB cases 
were calculated by comparing it with culture and 
DST results. AFB culture method utilised for the 
study was MGIT liquid culture test, and the DST 
used was liquid culture DST.
Statistics
The sensitivity, specificity, positive predic-
tive value and negative predictive value of Gen-
eXpert were calculated according to the following 
formula.
Sensitivity: (true positive / true positive + 
false negative) × 100 implies the test is positive 
when actually disease is present. Specificity: 
(true negative / true negative + false positive) 
× 100 implies the test is negative when actually 
disease is absent.
Positive predictive value (PPV): (true positive/ 
/true positive + false positive) × 100 calculates 
the probability that disease is present when the 
test is positive.
Negative predictive value:(true negative/ 
/true negative + false negative) × 100 calculates 
the probability that disease is absent when the 
test is negative.
By applying the above mentioned formulas to 
the contingency tables, the sensitivity, specificity, 
PPV and NPV of GeneXpert in the diagnosis and 
detection of rifampicin resistance in pulmonary 
and extrapulmonary TB cases were calculated.
Results
Our study enrolled 257 presumptive TB cases 
which included 132 pulmonary and 125 extrapul-
monary presumptive TB cases. On the basis of 
clinicoradiological and microbiological correla-
tion, diagnosis of TB was confirmed in 104 pul-
monary and 103 extrapulmonary cases. Of the 
103 extrapulmonary TB cases; 48 were lymph 
node TB cases, 31 were TB pleural effusion cas-
es, 11 were TB spine cases, 9 were other bone 
TB cases and 4 were TB meningitis cases. Out of 
a total of 104 pulmonary TB cases, 73 were rifam-
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picin-sensitive and 31 were rifampicin-resistant 
cases. 103 extrapulmonary TB cases included 
66 rifampicin-sensitive and 37 rifampicin-resis-
tant cases.
The sensitivity, specificity, positive predic-
tive value, negative predictive value of GeneX-
pert in diagnosis of pulmonary TB and detection 
of rifampicin resistance in pulmonary TB was 
95%, 93%, 98%, 84% and 96%, 100%, 100%, 
96%, respectively. The sensitivity, specificity, 
positive predictive value, negative predictive 
value of GeneXpert in diagnosis of extrapulmo-
nary TB and detection of rifampicin resistance in 
extrapulmonary TB cases was 79%, 86%, 96%, 
47% and 97%, 95%, 97%, 95%, respectively. 
The sensitivity, specificity, positive predictive 
value, negative predictive value of GeneXpert in 
diagnosis and detection of rifampicin resistance 
in lymph node TB cases was 77%, 80%, 95%, 
42% and 100%, 89%, 94%, 100%, respectively. 
Sensitivity, specificity, positive predictive value, 
negative predictive value of GeneXpert in diag-
nosis and detection of rifampicin resistance in 
TB pleural effusion cases was 71%, 100%, 100%, 
53% and 86%, 100%, 100%, 91%, respectively. 
Sensitivity, specificity, positive predictive value, 
negative predictive value of GeneXpert in diag-
nosis and detection of rifampicin resistance in 
TB spine cases was 100%, 100%, 100%, 100%, 
respectively. When compared to previous studies, 
sensitivity of GeneXpert in pleural effusion cases 
was higher in our study as pleural biopsy samples 
obtained through closed needle pleural biopsy 
were also subjected to analysis. Low sensitivity 
of GeneXpert in pleural fluid samples could be 
due to very low numbers of bacilli as in the ma-
jority of cases, the accumulation of pleural fluid 
results from hypersensitivity reaction to tuber-
culous antigen rather than direct invasion of the 
organism into the pleura. Sensitivity, specificity, 
positive predictive value, negative predictive 
value of GeneXpert in diagnosis and detection 
of rifampicin resistance in other bone TB cases 
was 100%, 100%, 90%, 100% and 100%, 100%, 
100%, 100%, respectively. Sensitivity, specifici-
ty, positive predictive value, negative predictive 
value of GeneXpert in diagnosis and detection 
of rifampicin resistance in CNS TB cases was 
75%, 100%, 100%, 100% and 100%, 100%, 100%, 
100%, respectively.
GeneXpert test was diagnostic in 13 AFB 
culture-negative extrapulmonary TB cases and 
5 culture-negative pulmonary TB cases. How-
ever, the test was false negative in 5 pulmonary 
and 21 extrapulmonary cases. GeneXpert test 
was false positive in all 5 cases, out of which 
2 were pulmonary and 3 were extrapulmonary 
cases. The sensitivity of AFB smear was lower 
than GeneXpert sensitivity in both pulmonary 
and extrapulmonary TB.
The 68 DR TB cases on further DST were 
diagnosed as 50 (24%) MDR TB, 17 (8%) PreX-
DR(FQ), and 1 (0.4% ) XDR TB cases. There were 
6 lymph node, 8 pulmonary, 2 spine and 1 CNS 
PRE XDR(FQ) TB cases. 
Discussion
TB is a curable disease if detected early and 
treated effectively, thus it is highly important 
to have efficient and cost-effective diagnostic 
tests. Early diagnosis and appropriate treatment 
of TB can help in improving cure rates, reducing 
transmission rates, morbidity and mortality. ZN 
smear microscopy carries high risk of false neg-
ative results due to low sensitivity and it doesn’t 
help to discriminate between drug susceptible 
and drug-resistant strains of MTB [2, 3]. These are 
owing to poor sample quality coupled with a need 
for technical expertise. Meanwhile, culture being 
the gold standard test for detecting MTB, requires 
several weeks to yield results, and largely depends 
on well-equipped laboratory facilities and skilled 
technicians [1]. Nucleic-acid-amplification tests 
provide more timely and accurate diagnosis of 
TB, thereby contributing to early initiation of TB 
treatment. GeneXpert test is an integrated fully 
automated nucleic-acid-amplification test that 
detects MTB and rifampicin resistance within 
90 mins. GeneXpert is a promising test with high 
sensitivity, specificity and rapid turnaround time 
[4–6]. The test is highly efficacious in pulmonary 
TB cases when compared to extrapulmonary cas-
es. In addition, GeneXpert test is likely to improve 
the diagnostic accuracy of TB at places where 
AFB culture or DST facilities are not available.
In our study, the performance of GeneXpert 
test was analysed with pulmonary and extrapul-
monary samples. Overall sensitivity, specificity, 
positive predictive value, negative predictive 
value of GeneXpert in diagnosis and detection 
of rifampicin resistance in pulmonary TB cases 
was 95%, 93%, 98%, 84% and 96%, 100%, 100%, 
96%, respectively. In extrapulmonary TB cases, 
sensitivity, specificity, positive predictive value, 
negative predictive value of GeneXpert in diag-
nosis and detection of rifampicin resistance cases 
was 79%, 86%, 96%, 47% and 97%, 95%, 97%, 
95%, respectively. These results are consistent 
with Cochrane metaanalaysis. Previous studies 
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of the GeneXpert test have reported sensitivities 
of 47 to 90% in smear-negative, culture-positive 
pulmonary tuberculosis cases and 98 to 100% in 
cases of smear-positive, culture-positive pulmo-
nary tuberculosis, with the specificity of GeneX-
pert being 99% to 100% [2, 12].
In the study conducted by Boehme et al,. 
the sensitivity was 99.8% for smear and cul-
ture-positive cases and 90.2% for smear-negative, 
culture-positive cases [13]. The sensitivity and 
specificity of the GeneXpert test in smear- and 
culture-positive pulmonary specimens was 98% 
and 100%, respectively, which was consistent 
with data of previous studies. For smear-negative 
pulmonary specimens, the sensitivity of the test 
was 88%, which is higher than that of Armand 
et al., and specificity was 100% comparable 
with previous studies [14]. For extrapulmonary 
smear-positive samples, sensitivity and specificity 
of GeneXpert was 100%, whereas for extrapul-
monary smear-negative samples, sensitivity and 
specificity was 67% and 100%, respectively. The 
sensitivity and specificity for detecting rifampicin 
resistance in pulmonary and extrapulmonary sam-
ples was 96% , 100% and 97%, 95%, respectively, 
with respect to culture as reference standard.
Diagnosing extrapulmonary TB infection is 
quite challenging when compared to pulmonary 
TB due to significant low numbers of the organ-
isms that can be recovered in the extrapulmo-
nary samples. In our study, we found that the 
GeneXpert test was more sensitive in detecting 
spine and bone TB cases than pleural effusion 
and lymph node TB cases. The detection rate 
of MTB among smear-negative non-respiratory 
specimens by the GeneXpert test varies between 
studies with sensitivity rate of 20-66%. As per 
studies by Armand et al., Causse et al., Tortoli 
et al. and Boehme et al., GeneXpert sensitivity 
in lymph node samples using AFB culture as 
reference standard, ranged from 50% to 100% 
[13–16]. Sensitivity and specificity of GeneXpert 
in lymph node TB cases was 83.1% and 93.6%, 
respectively, according to Denkinger metaanalysis 
[17]. Our study results of GeneXpert sensitivity 
in lymph node TB cases were 77%, which was 
comparable with previous studies.
Metaanalysis findings of Denkinger et al. 
revealed sensitivity and specificity of this test 
among pleural fluid to be 46% and 99%, respec-
tively [17]. Another metaanalysis findings of E. 
Penz et al. suggested sensitivity amongst pleural 
fluid was 37% and specificity of 98% [18]. How-
ever, in our study, sensitivity and specificity of 
GeneXpert in pleural effusion cases were 71% and 
100%, respectively. According to Denkinger meta-
analysis, sensitivity and specificity of GeneXpert 
in CNS TB was 81% and 98%, respectively [17]. 
As per study done by Penz et al., sensitivity and 
specificity of GeneXpert in CNS TB was 69% and 
97%, respectively [18]. In our study, sensitivity 
and specificity of GeneXpert in CNS TB was 75% 
and 100 %, respectively, and was consistent with 
previous studies.
Sensitivity and specificity of GeneXpert in 
bone TB as per study conducted by Held M. was 
95% and 96%, respectively [19]. Our results in 
bone TB were consistent with previously reported 
data.
In routine practice, the GeneXpert test is fast-
er when compared to culture [4-6]. The GeneXpert 
test was positive for 163 of 194 culture-positive 
and 19 of 64 culture-negative samples from tuber-
culosis cases. In our study, the sensitivity of the 
GeneXpert test was found to be higher as that of 
culture in pulmonary cases, whereas lower than 
AFB culture in extrapulmonary samples. There 
were 5 and 21 false negative cases of GeneX-
pert for pulmonary and extrapulmonary cases, 
respectively. For AFB culture test, there were 
5 and 13 false negative results in pulmonary and 
extrapulmonary samples, respectively. GeneXpert 
test was positive for all except for one smear-pos-
itive specimen, but the smear was positive only 
for 88 of 181 the GeneXpert test M.TB detected 
specimens. The sensitivity of microscopy was 
58% (62/101) for culture-positive pulmonary 
specimens and 24% (26/93) for culture-positive 
extrapulmonary specimens. Therefore, the sen-
sitivity of the GeneXpert test which was as rapid 
as smear was much higher than that of smear.
Smear-negative TB cases pose a challenge for 
the TB control programmes as they are associated 
with delayed or failure of diagnosis, unnecessary 
initiation of empirical tuberculous therapy and 
high risk of transmission. Therefore, the use of 
GeneXpert test, especially in countries with high 
TB prevalance like India, will help in rapid di-
agnosis and better treatment outcomes of smear- 
negative TB cases.
In our study, GeneXpert test was false posi-
tive in two pulmonary cases and 3 extrapulmo-
nary cases. False positivity of GeneXpert test 
results has been reported previously and occurs 
because of the presence of dead MTB in the test 
samples, particularly among previously treated 
patients. There are highly likely chances for such 
patients to receive avoidable anti-TB therapy. 
Hence, careful history taking with emphasis on 
previous treatment with anti-TB drugs is essential 
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to prevent unnecessary treatment of such false 
positive cases.
Our study included 31 pulmonary and 37 ex-
trapulmonary DR TB cases. The percentage of 
DR-TB (24%) cases in our study was higher when 
compared to the results of previous researches 
[20-22] due to referral bias, and it does not indi-
cate true prevalence of DRTB in the population.
GeneXpert is useful for rapid detection of 
TB and identification of rifampicin resistance, 
especially in a high prevelance country like India. 
The results are superior to smear microscopy and 
comparable to culture with shorter turnaround 
time. We recommend using it in routine TB di-
agnosis as this will help in early diagnosis and 
the management of patients with presumptive 
TB. The test results must always be confirmed by 
culture and further DST in clinically discordant 
and DRTB cases.
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